SLC5A2 and diabetes mellitus: A relatively new class of therapeutic agents, sodium–glucose cotransporter 2 (SGLT2) inhibitors, which were originally developed to improve glucose control by promoting glucosuria, have demonstrated powerful kidney and cardiovascular benefits and reduced mortality in patients with diabetes (3–5).